Orthogonal Testing Unravels a Novel ROS1 Oncogenic Fusion Variant (<i>ROS1-GPM6A</i>): A Practical Approach to Molecular Testing for Actionable Fusion Variants-Reference-Cited by-同舟云学术

Orthogonal Testing Unravels a Novel ROS1 Oncogenic Fusion Variant (ROS1-GPM6A): A Practical Approach to Molecular Testing for Actionable Fusion Variants

Published:2023-04 Issue:7 Volume: Page:
ISSN:2473-4284
Container-title:JCO Precision Oncology
language:en
Short-container-title:JCO Precision Oncology

Author:

Narvel Hiba G.¹^ORCID,Kim So Yeon²,Shokrekhuda Aspan M.³,Cohen Perry R.⁴^ORCID,Ramesh K. H.⁴,Solomon Sheila R.⁵^ORCID,Paik Paul K.⁶^ORCID,Halmos Balazs⁷^ORCID

Affiliation:

1. Department of Internal Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY

2. Department of Medical Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT

3. Department of Radiology, Division of Nuclear Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY

4. Department of Pathology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY

5. Guardant Health, Redwood City, CA

6. Department of Thoracic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY

7. Department of Medical Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/PO.22.00593

Reference28 articles.

1. ROS1-dependent cancers — biology, diagnostics and therapeutics

2. Molecular Pathways: ROS1 Fusion Proteins in Cancer

3. Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins

4. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Entrectinib;Reactions Weekly;2024-03-09

2. CD74/SLC34A2-ROS1 Fusion Variants Involving the Transmembrane Region Predict Poor Response to Crizotinib in NSCLC Independent of TP53 Mutations;Journal of Thoracic Oncology;2023-12